Report Highlights

Infection control in air at a turning point: Market Overview

The global infection control in air market stands at USD 6.8 billion in 2024, having undergone a structural reset following the COVID-19 pandemic. What began as an emergency procurement surge has matured into institutionalised demand, with healthcare systems, commercial real estate developers, and school districts embedding airborne infection control into long-term capital budgets. The market is no longer reactive. Hospital systems such as the UK's NHS and the US Veterans Affairs network have codified indoor air quality standards into their facility management contracts, creating recurring procurement cycles rather than one-off purchases. The dominant structural shift underway is the migration from portable air filtration toward permanently integrated, building-level HVAC-based disinfection systems that combine HEPA filtration, UV-C irradiation, and real-time air quality sensing.

The current moment is a genuine inflection point for infection control in air, driven by three converging regulatory developments. ASHRAE Standard 241, introduced in 2023 and entering commercial enforcement phases through 2025–2026, mandates minimum equivalent clean air delivery rates for occupied spaces across the United States. The European Centre for Disease Prevention and Control has issued parallel indoor air quality guidance that is being transposed into national building codes across Germany, France, and the Netherlands. Simultaneously, post-pandemic liability awareness among facility operators has elevated airborne infection control from an optional upgrade to a fiduciary obligation, fundamentally altering the buyer's decision calculus and compressing sales cycles for compliant system providers.

Key Forces Shaping Infection Control in Air Growth

Three specific forces are propelling revenue growth across this market. First, regulatory codification of indoor air quality standards is the most powerful near-term driver. ASHRAE 241 and its European equivalents create non-discretionary procurement across commercial and institutional segments, directly benefiting manufacturers of integrated HVAC disinfection modules such as Carrier Global and Daikin Industries. Second, healthcare-acquired infection cost burden is accelerating hospital investment. The US Centers for Disease Control estimates healthcare-acquired infections cost the American hospital system USD 28.4 billion annually; airborne pathogens account for a disproportionate share in high-density ward settings, making the ROI case for UV-C and HEPA system upgrades quantifiably compelling for CFOs and procurement committees.

Third, and critically underweighted by consensus analysis, is the expansion of infection control requirements into non-healthcare commercial real estate. Office landlords facing post-pandemic occupancy challenges are using certified air quality as a tenant retention and leasing premium tool. CBRE's 2024 occupier survey found that 54% of corporate tenants now include indoor air quality certification as a lease negotiation criterion. This creates a durable commercial real estate demand channel that persists independently of any future pandemic risk perception, benefiting segments such as commercial-grade air purification and building management system-integrated sensors. Asia Pacific manufacturing facilities represent the third high-growth geography, driven by pharmaceutical GMP compliance requirements tightening under China's NMPA and India's CDSCO regulatory frameworks.

Barriers and Risks in the Infection Control in Air Market

The most significant structural barrier is installation complexity and retrofit cost in legacy building stock. The majority of commercial buildings constructed before 2010 lack the ductwork geometry, electrical capacity, and control infrastructure required for fully integrated HVAC disinfection systems. Retrofitting a mid-size commercial building in the United States carries average costs of USD 180,000–USD 340,000, creating budget resistance outside of healthcare and premium commercial segments. This is a permanent structural constraint for the addressable market, not a cyclical one. It systematically limits penetration in the education and affordable housing segments despite strong latent demand, and it favors modular, decentralised solutions over building-integrated platforms in retrofit contexts.

The more immediately dangerous cyclical risk is demand volatility tied to pandemic threat perception. Market data from 2022–2023 demonstrated a measurable pullback in discretionary air quality investment as COVID-19 risk receded from public attention, with portable air purifier shipments declining 18% year-over-year in the US consumer segment per GfK retail data. If no new respiratory pathogen threat materialises within the forecast window, institutional budgets outside healthcare face competitive pressure from other capital priorities. The structural risk of retrofit cost constrains ceiling; the cyclical risk of attention fatigue constrains floor. Together they create a growth corridor that, while durable, is narrower than the most optimistic post-pandemic projections suggested in 2021.

Emerging Opportunities in Infection Control in Air

The most credible near-term opportunity is the convergence of air disinfection with smart building IoT platforms. Companies such as Honeywell International and Johnson Controls are actively integrating real-time pathogen load sensing with automated disinfection response systems — a proposition that moves infection control from passive filtration to active threat management. This opportunity materialises as building operators seek unified ESG and occupant health reporting dashboards, which large corporate tenants now require from landlords. The condition that must be met is standardisation of pathogen sensor protocols, currently fragmented across incompatible data formats, which is expected to consolidate under ISO 16000 series amendments anticipated in 2026.

A second distinct opportunity lies in the Asian pharmaceutical manufacturing sector. Tightening GMP air quality standards across China's NMPA-regulated facilities and India's CDSCO-compliant export-oriented plants are mandating cleanroom-grade infection control upgrades across hundreds of facilities through 2028. This segment demands high-specification laminar flow and HEPA H14-grade filtration products, commanding significantly higher unit economics than standard commercial installations. The entry condition is local regulatory approval and the ability to provide validated IQ/OQ/PQ documentation, which currently limits the field to Camfil, AAF International, and a small number of regional specialists. Western majors that localise certification processes in India and China before 2026 capture this window before domestic Chinese competitors scale comparable offerings.

Investment Case: Bull, Bear, and What Decides It

The bull case for infection control in air rests on regulatory compulsion creating a durable, non-cyclical demand floor. If ASHRAE 241 enforcement proceeds on schedule and European national building code transpositions complete by 2026, the addressable commercial market expands by an estimated USD 3.2 billion in mandatory replacement and upgrade spend over three years. Simultaneously, a new respiratory pathogen event — the base rate for novel outbreak emergence has not decreased — would trigger a second institutional procurement surge layered on top of the regulatory baseline. In this scenario, integrated platform providers with established service contracts, particularly Carrier Global and Honeywell, generate outsized recurring revenue growth, and the market reaches USD 16 billion by 2034, well above consensus.

The bear case centres on enforcement gaps and budget substitution. Regulatory mandates are only as powerful as their enforcement mechanisms, and ASHRAE 241 lacks direct federal enforcement authority in the United States, relying on state-level adoption that remains uneven. If fewer than 30 states mandate compliance by 2027, the commercial demand surge is muted and concentrated in voluntary early adopters. Additionally, if post-pandemic institutional budgets prioritise workforce costs over capital infrastructure, air infection control competes poorly against more visible spending categories. Margin compression from low-cost Chinese UV-C and HEPA manufacturers entering Western distribution channels — Guangdong-based units are now undercutting established brands by 35–45% on e-procurement platforms — erodes revenue growth even where unit volume holds.

The single swing variable is the pace and depth of state-level ASHRAE 241 adoption in the United States. This one factor determines whether the commercial segment becomes a USD 3 billion mandatory replacement market or remains a fragmented, voluntary-upgrade market growing at half the projected rate. Jurisdictions that adopt ASHRAE 241 into building codes pull forward multi-year demand into concentrated procurement windows; jurisdictions that delay keep institutional buyers in a wait-and-see posture. No other factor — not a new pandemic, not smart building integration, not pharmaceutical GMP tightening — has comparable scale impact on the 2026–2029 revenue trajectory that defines whether the bull or bear case prevails.

Market at a Glance

Regional Performance: Where Infection Control in Air Is Growing Fastest

North America is the largest revenue contributor, accounting for an estimated 38% of global market value in 2024, anchored by dense healthcare infrastructure, the ASHRAE 241 regulatory catalyst, and the highest per-facility spending on infection control of any region. Europe holds the second-largest share at approximately 27%, with Germany and the UK leading institutional investment and the Nordic countries demonstrating the highest per-capita spend on commercial building air quality upgrades. Latin America remains small in absolute terms but is growing from a low base as Brazil and Mexico expand private hospital networks that adopt international infection control standards for accreditation purposes.

Asia Pacific carries the highest regional growth rate at an estimated 10.8% CAGR through 2034, driven by three distinct demand streams: pharmaceutical manufacturing GMP compliance in India and China, rapid hospital construction in Southeast Asia particularly Vietnam and Indonesia, and urban air quality anxiety in Tier 1 Chinese cities driving premium residential and commercial air purification demand. The Middle East and Africa region is growing steadily at approximately 7.2% CAGR, concentrated in Gulf Cooperation Council countries where new hospital construction projects embed HEPA and UV-C systems as standard specification. India deserves specific attention as a breakout market: its domestic pharmaceutical export sector and government-mandated hospital infrastructure upgrades under the Ayushman Bharat scheme position it as the second-fastest growing individual country market through 2028.

Leading Market Participants

• Daikin Industries
• Honeywell International
• Carrier Global
• Koninklijke Philips
• STERIS plc
• Camfil AB
• AAF International
• Xenex Disinfection Services
• Johnson Controls International
• LG Electronics

Where Is Infection Control in Air Headed by 2034

By 2034, the infection control in air market reaches USD 14.7 billion and is characterised by a bifurcated competitive structure: a consolidated tier of four to five integrated platform providers commanding the healthcare and commercial HVAC segments, and a fragmented tier of regional specialists serving pharmaceutical cleanroom, residential premium, and niche institutional channels. The dominant technology by installed base shifts from portable HEPA units to permanently integrated UV-C plus HEPA hybrid systems embedded in building management platforms with real-time pathogen sensing. The standalone portable air purifier, dominant in 2020–2022, becomes a secondary channel serving residential and SME segments where full integration is not economically viable.

Among current participants, Carrier Global and Honeywell International are best positioned for 2034 because both have the HVAC infrastructure footprint, building management system software capability, and global service networks required to dominate the integrated platform tier. Camfil AB is best positioned in the pharmaceutical filtration segment given its H14 HEPA certification depth and established regulatory validation documentation infrastructure. The most significant competitive risk to incumbents comes from Chinese manufacturers — specifically Midea Group and its subsidiary Coway Korea distribution partnerships — which are scaling UV-C and HEPA integrated units with 30–40% cost advantages and are targeting European commercial and residential channels aggressively through 2026 and beyond.

Market Segmentation

By Product Type

• HEPA Air Filtration Systems
• UV-C Germicidal Irradiation Devices
• Photocatalytic Oxidation Systems
• Ionisation and Plasma Air Purifiers
• Antimicrobial HVAC Modules
• Hybrid Multi-Technology Systems

By End User

• Hospitals and Acute Care Facilities
• Pharmaceutical and Cleanroom Facilities
• Commercial Office Buildings
• Educational Institutions
• Residential
• Transportation Infrastructure

By Technology Integration

• Standalone Portable Units
• HVAC-Integrated Systems
• Smart IoT-Connected Platforms
• Ceiling-Mounted Fixed Units

By Distribution Channel

• Direct Sales and Specification
• HVAC Contractor Networks
• Online and E-Procurement
• Healthcare Group Purchasing Organisations
• Retail and Consumer Electronics

Frequently Asked Questions

Q1. What is the single most important regulatory catalyst for the infection control in air market through 2028? ▼

ASHRAE Standard 241, mandating minimum clean air delivery rates in occupied commercial spaces, is the primary regulatory catalyst. Its state-level adoption pace in the US directly determines the scale and timing of mandatory commercial replacement spend through 2028.

Q2. Which technology segment offers the strongest revenue growth within this market? ▼

HVAC-integrated hybrid systems combining UV-C irradiation and HEPA H13/H14 filtration represent the fastest-growing technology segment. Their multi-year service contract structure generates recurring revenue that standalone portable units cannot replicate.

Q3. Is the post-COVID demand base durable or subject to structural decline? ▼

The healthcare and pharmaceutical segments represent durable, regulation-anchored demand that does not depend on pandemic risk perception. The commercial and residential segments carry cyclical vulnerability, but ASHRAE 241 enforcement is progressively converting discretionary spend into mandatory compliance procurement.

Q4. Which geography presents the most attractive near-term investment entry point? ▼

India presents the strongest near-term entry case, combining pharmaceutical GMP upgrade mandates, government hospital infrastructure expansion under Ayushman Bharat, and a competitive landscape that remains open to Western technology providers before domestic alternatives scale fully.

Q5. How significant is the competitive threat from Chinese manufacturers to established Western players? ▼

The threat is material and accelerating. Guangdong-based UV-C and HEPA manufacturers are undercutting Western brands by 35–45% on commercial e-procurement platforms and are actively building European distribution networks, with meaningful market share displacement expected in non-regulated commercial segments by 2027.